After months of delays, three bills are finally scheduled for hearings before the Senate and the Assembly Budget and Appropriations Committee.
On November 26, 2018, the Senate and Assembly committees will consider the bill introduced by Senators Scutari and Sweeney, S2703, to legalize adult use marijuana; and bills to revise medical marijuana laws introduced by Senators Vitale, Scutari and O’Scanlan, S10 and S2426. Identical companion bills have been introduced in the assembly as well.
Rumors about these hearings have circulated for months but were delayed as legislators ...
- August 29, 2018 | Memorandum on Guidance Regarding Municipal Prosecutors’ Discretion in Prosecuting Marijuana and Other Criminal Offenses
- July 16, 2018 | New Jersey Department of Health Division of Medical Marijuana Request for Applications
- July 3, 2018 | NY Department of Financial Services Guidance on provision of Financial Services to Medical Marijuana and Industrial Hemp-Related Business in New York State
- April 30, 2018 | State Treasurers Cannabis Banking Solution
- March 23, 2018 | NJ Health Dep't Executive Order 6 Report Final
- January 23, 2018 | Executive ...
On October 25, the C. Willard Heckel Inn of Court at Rutgers Law School starts the new semester with a presentation on New Jersey cannabis law. Sean Mack, co-chair of Pashman Stein Walder Hayden’s Litigation Group and Leader of the Firm’s Cannabis Law Group will provide an overview of the status of medical cannabis in New Jersey. Sean will be speaking on the proposed or enacted legislation to expand medical cannabis and adult use cannabis.
The program will be held from 5 p.m. to 7 p.m. at Rutgers Law School, Center for Law and Justice, 123 Washington Street, Newark, NJ 07102.
To register ...
After decades of advocates asking for cannabis to be removed as a Schedule I drug, on September 28, 2018, the DEA recognized that cannabis can have medicinal value and therefore the cannabis drug Epidiolex cannot be a Schedule I drug. Schedule I is reserved for drugs that have “no medicinal value” and have the potential to be highly addictive.
Specifically the DEA concluded that “Epidiolex no longer meets the criteria for placement in schedule I of the CSA.”
On June 25, 2018 the FDA had approved Epidiolex “for the treatment of seizures associated with two rare and severe forms ...
A recent poll by Quinnipiac University found that while approximately 62% of New Jersey residents are in favor of fully legalizing marijuana, only roughly 50% want it to be sold within their towns. 45% affirmatively said they do not want it in their towns. So far, at least 30 towns in New Jersey have passed laws to ban cannabis businesses.
What does this mean for the cannabis industry? Obviously, those wanting to pursue medical or adult-use cannabis licenses in the future need to pay close attention to what is occurring at the local government level. Building relationships with ...
Currently, there are six alternative treatment centers (aka medical marijuana dispensaries) in New Jersey, but that number is soon to double. On July 16, 2018, the New Jersey Department of Health Division of Medicinal Marijuana issued a Request for Applications for up to six more medical dispensaries. The six licenses will be divided evenly throughout the state: two in the northern region, two in central region, and two in the southern region.
Importantly, while all current medical marijuana licensees are required to be non-profit corporations, the six new licenses can be ...
The Canadian federal government legalized marijuana yesterday when the Cannabis Act was approved by the Senate in a 52-29 vote. The underlying basis for the legislation, which is set forth in an official press release when the law was first proposed makes perfect sense, and is something that every American anti-prohibition advocate can relate to: “The current approach to cannabis does not work. It has allowed criminals and organized crime to profit, while failing to keep cannabis out of the hands of Canadian youth.” While the Canadian legislation is significant for several ...
On June 18, 2018, the NJ Department of Health published for comment its anticipated amendments to the administrative rules for NJ’s medical marijuana program. Interested parties will have 60 days to submit comments on the proposed rules. Comments can be submitted electronically at: http://www.nj.gov/health/legal/ecomments.shtml,
According to a DOH press release, the new rules would make the following changes:
- Reducing the registration fee for qualifying patients and their caregivers from $200 to $100
- Adding seniors and military veterans to those eligible for the reduced ...
Until now, New Jersey’s strategy for marijuana legalization has been to address medical marijuana separately from recreational marijuana. Thus, as we have previously reported, Governor Murphy and the Department of Health have been working to rapidly expand the medical program, while the Legislature separately hashes out legislation on full legalization.
Now, a new approach has emerged. Senator Scutari, a legislative leader in the legalization movement, has introduced the “New Jersey Marijuana Legalization Act,” which will tackle both medical and recreational ...
Moody’s Investors Service, Inc., a leading credit ratings, research, and risk analysis company, confirmed today that legalized marijuana provides positive revenue for states and localities which have permitted retail sale of marijuana, even taking into account the cost of regulation. While the share of the general revenue provided by taxes and licensing fees is relatively small – 1.2 percent of the general revenue in Washington and 2 percent in California, for example – that is in line with Governor Phil Murphy’s projections, which have accounted for an additional $60 ...
